All News

Findings from a preplanned analysis assessing 2 clinical trials of bempegaldesleukin plus nivolumab in renal cell carcinoma and bladder cancer led to a decision to end the combination’s global clinical development program and discontinue all other ongoing clinical trials.

The phase 1/2 TakeAim Lymphoma trial examining emavusertib for patients with B-cell malignancies has received a partial clinical hold pending review by the FDA.

Patients with early stage non–small cell lung cancer and impaired pulmonary function could potentially benefit from treatment with stereotactic body radiotherapy.

Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.

Sam Klempner, MD, spoke about the importance of expanding minimal residual disease platforms for patients with gastrointestinal cancers.

TG Therapeutics made the decision to voluntarily pull the biologics license application and supplemental new drug application for ublituximab/umbralisib in patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

Patients with multiple myeloma and high-risk cytogenetics may benefit from treatment with high-dose therapy consolidation compared with delaying this approach.

This review provides an updated analysis of the literature and discusses the authors' approach to the diagnosis and treatment of patients with marginal zone lymphoma.

Brian Slomovitz, MD, spoke about previously conducted trials that used regimens involving pembrolizumab and chemotherapy for patients with newly diagnosed high-risk endometrial cancer at SGO 2022.

Investigators reported topline findings from the phase 1/2 EPCORE NHL-1 trial assessing epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

Nicolas Girard, MD, highlighted key findings from the CheckMate 816 trial, examining nivolumab and chemotherapy vs chemotherapy alone in resectable non–small cell lung cancer.

European patients with locally advanced or metastatic urothelial cancer can now receive treatment with enfortumab vedotin following treatment with a platinum-containing regimen and a PD-(L)1 inhibitor.

Frederick Lock, MD, spoke about how axicabtagene ciloleucel has improved survival in patients with large B-cell lymphoma.

Gennady Bratslavsky, MD, spoke about the role of adjuvant therapy in renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.

In an interview with CancerNetwork®, Paul Barr, MD, discusses 8-year follow-up data from the phase 3 RESONATE-2 trial, assessing first-line ibrutinib in patients 65 years of age or older with chronic lymphocytic leukemia.

The FDA has lifted its partial clinical hold on magrolimab and azacitidine studies for patients with acute myeloid leukemia and myelodysplastic syndrome.

In this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.

Ira Winer, MD, PhD, FACOG, spoke about high response rates observed in patients with pretreated platinum-resistant ovarian cancer from the phase 1/2 ARTISTRY-1 trial.

Phillip S. Low, PhD, spoke about what the future holds for treatments like 177Lu-PSMA-617 being developed for patients with prostate cancer.

J. David Prologo, MD, FSIR, ABOM-D, an interventional radiologist at Emory Healthcare, details how cryoablation can be used by radiologists to manage pain in patients with cancer.

Although canakinumab, pembrolizumab, and chemotherapy did not lead to an improvement in survival vs the placebo cohort, it may still have benefit in certain subgroups of patients with previously untreated locally advanced or metastatic non–small cell lung cancer.

Bria-IMT has been granted fast track designation by the FDA for the treatment of metastatic breast cancer.

“You have to look at the cell-free DNA results with a grain of salt and with some degree of sophistication in terms of what you can act on as a predictive biomarker in the blood.”

Data from the phase 2 KGOG 3046 trial revealed evidence of antitumor activity with the neoadjuvant chemoimmunotherapy regimen containing durvalumab and tremelimumab for patients with advanced-stage ovarian cancer.

Ursula A. Matulonis, MD, discusses key data with mirvetuximab soravtansine for patients with folate receptor α–high platinum-resistant ovarian cancer that read out of the phase 3 SORAYA trial.

Matthew Krebs, MB, PhD spoke about the reasoning for the phase 1 PALOMA trial in patients with solid tumors who received a subcutaneous formulation of amivantamab.

Liliana Bustamante, MD, and Richard Kim, MD, discuss circulating tumor DNA as a potential prognostic biomarker for patients with colorectal cancer.

Results of the phase 2 AURELIO-03 trial show SOT101 plus PD-1 inhibition induced responses in patients with advanced solid tumors.

A phase 3 trial of patients with extensive-stage small cell lung cancer who were treated with adebrelimab plus chemotherapy compared with matched placebo met the primary end point of overall survival.

The addition of an immune checkpoint inhibitor to CG0070 induced a complete response rate of 88.9% among 18 patients in the phase 2 CORE1 trial.